Literature DB >> 12116033

Demographic, clinical, and virological characteristics of hepatocellular carcinoma in Asia: survey of 414 patients from four countries.

Bao-En Wang1, Wei-Min Ma, Ali Sulaiman, Sjaifoellah Noer, Suwignyo Sumoharjo, Didacus Sumarsidi, Badri Nath Tandon, Kuniaki Nakao, Shunji Mishiro, Yuzo Miyakawa, Yoshihiro Akahane, Hiroshi Suzuki.   

Abstract

Demographic, etiological, clinical characteristics and treatment of hepatocellular carcinoma (HCC) were surveyed in 414 patients in Asia, including 107 from China, 15 from India, 101 from Indonesia and 191 from Japan. Males predominated in all countries, accounting for up to 75%. The mean +/- SD age at the development of HCC was about 10 years older for the patients from Japan (63.8 +/- 9.5, P < 0.001) and India (63.1 +/- 11.2, P < 0.05) than those from China (54.0 +/- 13.7) and Indonesia (53.7 +/- 14.2). Hepatitis B surface antigen (HBsAg) in serum was detected in 67% of patients from China who were tested, 27% from India, 21% from Indonesia and 18% from Japan, whereas antibody to hepatitis C virus was detected in 4%, 53%, 40% and 70%, respectively; co-occurrence of hepatitis B and C infections was seen only in 7%, 0%, 2%, and 1%, leaving an etiology other than hepatitis viruses in 22%, 20%, 36% and 11%. HCC was diagnosed primarily by ultrasonography in China (43%) and Japan (52%), and on physical examination in India (60%) and Indonesia (52%). The size of the largest tumor exceeded 5.0 cm in diameter only in 24% of the patients from Japan, much less often than in 67%, 87%, and 71%, respectively, of those from China, India and Indonesia (P < 0.001). The most favored treatment was chemolipidolization in China (81%) and Japan (81%), whereas it was transarterial embolization in India (13%) and Indonesia (26%). These results highlight common as well as distinct characteristics of HCC in Asia, and warrant the need for close cooperation toward early diagnosis and effective treatment of HCC. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12116033     DOI: 10.1002/jmv.10087

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

Review 1.  Hepatitis B virus infection in Indonesia.

Authors:  Yoshihiko Yano; Takako Utsumi; Maria Inge Lusida; Yoshitake Hayashi
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

2.  Liver cirrhosis and hepatocellular carcinoma in hepatic vena cava disease, a liver disease caused by obstruction of inferior vena cava.

Authors:  Santosh Man Shrestha
Journal:  Hepatol Int       Date:  2009-01-23       Impact factor: 6.047

3.  A4383C and C76G SNP in Cathepsin B is respectively associated with the high risk and tumor size of hepatocarcinoma.

Authors:  Tsung-Po Chen; Shun-Fa Yang; Chiao-Wen Lin; Hsiang-Lin Lee; Chiung-Man Tsai; Chia-Jui Weng
Journal:  Tumour Biol       Date:  2014-08-10

4.  Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide.

Authors:  Ahmed Zidan; Hubert Scheuerlein; Silke Schüle; Utz Settmacher; Falk Rauchfuss
Journal:  Hepat Mon       Date:  2012-10-24       Impact factor: 0.660

5.  Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients.

Authors:  T F Greten; F Papendorf; J S Bleck; T Kirchhoff; T Wohlberedt; S Kubicka; J Klempnauer; M Galanski; M P Manns
Journal:  Br J Cancer       Date:  2005-05-23       Impact factor: 7.640

Review 6.  Radiofrequency ablation versus laparoscopic hepatectomy for treatment of hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Shan Jin; Shisheng Tan; Wen Peng; Ying Jiang; Chunshan Luo
Journal:  World J Surg Oncol       Date:  2020-08-12       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.